# Brazil cannabis-derived CBD regulation

> Live situation record from CLSTR: https://clstr.news/situations/brazil-cannabis-derived-cbd-regulation
> Updated: 2026-08-21T12:15:00.000Z. Sources: 8. Developments: 2.

Brazil’s National Health Surveillance Agency (Anvisa) is finalizing new regulations to govern the magistral manipulation of cannabidiol (CBD) preparations. The agency has classified this regulatory work as a priority to address issues stemming from previous rules that excluded compounding pharmacies from working with cannabis-derived products.

By allowing pharmacies to compound CBD isolate with a minimum purity of 98%, the forthcoming norm aims to reduce legal uncertainty, improve patient access, and decrease the reliance on judicial interventions to secure supplies.

## Timeline

### 2026-08-21: Anvisa and Dinavisa sign agreement to combat illegal products

Anvisa and Paraguay’s Dinavisa signed a five-year agreement to combat counterfeit and smuggled products, targeting the rising circulation of unauthorized medications at the border.

8 sources. https://clstr.news/cluster/anvisa-and-dinavisa-sign-agreement-to-combat-illegal-products

### 2026-08-04: Brazil's Anvisa advances rules for magistral CBD cannabis preparations

Anvisa is finalising a rule to allow Brazilian pharmacies to compound high‑purity CBD isolates, ending a regulatory gap that spurred court battles and supply shortages.

2 sources. https://clstr.news/cluster/brazils-anvisa-advances-rules-for-magistral-cbd-cannabis-preparations

---
Cite as: Brazil cannabis-derived CBD regulation. CLSTR, https://clstr.news/situations/brazil-cannabis-derived-cbd-regulation